Herbert Irving Comprehensive Cancer Center

      

    

    

      

        


                Flash Section

        

        
HICCC

      

      

      

            








        












  

        
Welcome to the Cancer Center's clinical trials online search tool. Clinical trials are studies designed to test the effectiveness of new treatments, including new drugs or new combinations of drugs. For additional information about these trials, call the Cancer Center's Clinical Research Management Office at (212) 305-8615.


    

        

        

            
Study ID Search

            
            
        

        

        
    


    

        
Advanced Search Form

        

        

            Group(s)
            
			 			 Adults
							 			     Pediatrics
				            
            
                
            
        

        

            
             
        

        

            

        
        

        

        
    




   
1 Results

           


            
Kidney, Liver, Soft Tissue, Thyroid


            
ID:AAAJ4351


                
 Cooperative Group

                Principal Investigator: Dr. Alice Lee


            

                Pediatrics:

                ADVL1121: A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib
(IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms
Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma            



            

                This is a phase II, multi-center study of Sorafenib, an agent that acts as a control in tumor growth. The purpose of this study is to determine the response rate to as well as evaluate the toxicities of Sorafenib in children and young adults with relapsed (cancers that have come back after being treated before) Rhabdomyosaroma, Wilma Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma. Sorafenib will be given every 12 hours as tablets. The therapy will last up to 28 days and the doctor may ask you to visit after to complete follow-up tests. Participants can receive up to 24 cycles of therapy continuously. There will be about 80 patients participating in this study overall and about 6 will be treated at Columbia University Medical Center. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with solid tumors. Please click here to view more information in ClinicalTrials.gov.				  


            
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.

                   









  


  

    

        


       

  












                

                

            


	      


  
 bottom